BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30668221)

  • 1. PEGylated trimethylchitosan emulsomes conjugated to octreotide for targeted delivery of sorafenib to hepatocellular carcinoma cells of HepG2.
    Varshosaz J; Raghami F; Rostami M; Jahanian A
    J Liposome Res; 2019 Dec; 29(4):383-398. PubMed ID: 30668221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. pH-responsive hyaluronic acid nanoparticles coloaded with sorafenib and cisplatin for treatment of hepatocellular carcinoma.
    Zhang W; Cai J; Wu B; Shen Z
    J Biomater Appl; 2019 Aug; 34(2):219-228. PubMed ID: 31084233
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma.
    Varshosaz J; Fard MM; Mirian M; Hassanzadeh F
    Anticancer Agents Med Chem; 2020; 20(3):346-358. PubMed ID: 31566137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.
    Tunki L; Kulhari H; Vadithe LN; Kuncha M; Bhargava S; Pooja D; Sistla R
    Eur J Pharm Sci; 2019 Sep; 137():104978. PubMed ID: 31254645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
    Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
    Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and characterization of parthenolide nanocrystals for enhancing therapeutic effects of sorafenib against advanced hepatocellular carcinoma.
    Liang P; Wu H; Zhang Z; Jiang S; Lv H
    Int J Pharm; 2020 Jun; 583():119375. PubMed ID: 32344021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of pectin-deoxycholic acid conjugate for targeted delivery of anticancer drugs in hepatocellular carcinoma.
    Varshosaz J; Sadri F; Rostami M; Mirian M; Taymouri S
    Int J Biol Macromol; 2019 Oct; 139():665-677. PubMed ID: 31377298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioinspired nanocarriers for an effective chemotherapy of hepatocellular carcinoma.
    Xu L; Wu S; Zhou X
    J Biomater Appl; 2018 Jul; 33(1):72-81. PubMed ID: 29699442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma.
    Gan H; Chen L; Sui X; Wu B; Zou S; Li A; Zhang Y; Liu X; Wang D; Cai S; Liu X; Liang Y; Tang X
    Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():395-403. PubMed ID: 30033270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Synergistic Cytotoxic Effect of Laser-Irradiated Gold Nanoparticles and Sorafenib Against the Growth of a Human Hepatocellular Carcinoma Cell Line.
    Ebrahim HM; El-Rouby MN; Morsy ME; Said MM; Ezz MK
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3369-3376. PubMed ID: 31759361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells.
    Tang H; Chen D; Li C; Zheng C; Wu X; Zhang Y; Song Q; Fei W
    Int J Pharm; 2019 Dec; 572():118782. PubMed ID: 31678528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
    Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
    Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma.
    Tom G; Philip S; Isaac R; Praseetha PK; Jiji SG; Asha VV
    Life Sci; 2018 Aug; 206():10-21. PubMed ID: 29709652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
    Zhang L; Gong F; Zhang F; Ma J; Zhang P; Shen J
    Int J Nanomedicine; 2013; 8():1517-24. PubMed ID: 23620667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib-loaded polymeric micelles as passive targeting therapeutic agents for hepatocellular carcinoma therapy.
    Su Y; Wang K; Li Y; Song W; Xin Y; Zhao W; Tian J; Ren L; Lu L
    Nanomedicine (Lond); 2018 May; 13(9):1009-1023. PubMed ID: 29630448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
    Bian Y; Guo D
    Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreasing acute toxicity and suppressing colorectal carcinoma using Sorafenib-loaded nanoparticles.
    Li N; Chen Y; Sun H; Huang T; Chen T; Jiang Y; Yang Q; Yan X; Wu M
    Pharm Dev Technol; 2020 Jun; 25(5):556-565. PubMed ID: 31958240
    [No Abstract]   [Full Text] [Related]  

  • 19. Polymeric micelles based on PEGylated chitosan-g-lipoic acid as carrier for efficient intracellular drug delivery.
    Liu G; Li K; Wang H
    J Biomater Appl; 2017 Feb; 31(7):1039-1048. PubMed ID: 28178903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel oleanolic acid-loaded PLGA-TPGS nanoparticle for liver cancer treatment.
    Bao X; Gao M; Xu H; Liu KX; Zhang CH; Jiang N; Chu QC; Guan X; Tian Y
    Drug Dev Ind Pharm; 2015; 41(7):1193-203. PubMed ID: 25026246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.